Allogeneic HB-adMSCs
Small molecule
Allogeneic HB-adMSCs is one of 40 small molecule programs targeting Acute Kidney Injury. It is currently in development.
1
Indications
1
Total Trials
1
Active Trials
39
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
178 competitors in Acute Kidney Injury
#DrugCompanyPhaseTrials
1Giapreza
LLa Jolla Pharmaceutical Company
Phase 3
Crestor
AstraZenecaPreclinical
Pentoxyphylline
NNational Taiwan University Hospital
Phase 3
Proamatine
TakedaPreclinical
Cymbalta
Alnylam PharmaceuticalsPreclinical
Celexa
AbbViePreclinical
Lexapro
AbbViePreclinical
Lescol
NovartisPreclinical
Golytely
BayerPreclinical
Vancocin
HHikma Pharmaceuticals LLC
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Allogeneic HB-adMSCs. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Company
- HHope Biosciences LLC